SCHEMBL25619355

SCHEMBL25619355

O=C(O)CCCCCCCC(O)CCCCCCCOCc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.49
MAPT P10636 1/20 0.49
RXFP1 Q9HBX9 1/20 0.49
FFAR4 Q5NUL3 1/20 0.47
FFAR1 O14842 1/20 0.47
FOLH1 Q04609 1/20 0.47
TRPA1 O75762 1/20 0.46
PTGER1 P34995 1/20 0.45
PTGFR P43088 1/20 0.45
PTGER2 P43116 1/20 0.45
FAAH O00519 1/20 0.45
LTB4R Q15722 1/20 0.44
TRPV1 Q8NER1 1/20 0.44
MMP3 P08254 1/20 0.44
MMP9 P14780 1/20 0.44
MMP8 P22894 1/20 0.44
HDAC3 O15379 1/20 0.44
MAPK1 P28482 1/20 0.44
ADRA1A P35348 1/20 0.44
HDAC4 P56524 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1008067 0.89 MAPT (0.59) EPHX2MAPTRXFP1FFAR1FOLH1
SCHEMBL5508985 0.89 MAPT (0.59) EPHX2MAPTRXFP1FFAR1FOLH1
SCHEMBL2871485 0.89 MAPT (0.59) EPHX2MAPTRXFP1FFAR1FOLH1
SCHEMBL25238062 0.89 CA1 (0.50) EPHX2TRPA1MMP3MMP9MMP8
SCHEMBL2867823 0.89 MAPT (0.59) EPHX2MAPTRXFP1FFAR1FOLH1
SCHEMBL23117118 0.89 CA1 (0.50) EPHX2TRPA1MMP3MMP9MMP8
SCHEMBL830483 0.89 MAPT (0.59) EPHX2MAPTRXFP1FFAR1FOLH1
SCHEMBL19032486 0.89 CA1 (0.50) EPHX2TRPA1MMP3MMP9MMP8
SCHEMBL1007119 0.89 MAPT (0.59) EPHX2MAPTRXFP1FFAR1FOLH1
SCHEMBL8984468 0.89 MAPT (0.59) EPHX2MAPTRXFP1FFAR1FOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230181482-A1 LIPIDS FOR DELIVERY OF NUCLEIC ACID SEGMENTS ASTRAZENECA AB (SE) 2023-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230181482-A1 LIPIDS FOR DELIVERY OF NUCLEIC ACID SEGMENTS SNRPA, F12, ABCB4 EPHX2 2992/4885MAPT 4161/4885RXFP1 793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.